Tetanus Antibody, IgG
Ordering Recommendation

Evaluate the ability of a patient to produce antibody to pure protein vaccine after vaccination to rule out antibody deficiency.

Quantitative Multiplex Bead Assay
1-2 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Serum separator tube. "Post" specimen should be drawn 30 days after immunization. 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL) "Pre" and "post" vaccine specimens can be submitted separately or together for testing; if shipped separately, "post" specimen must be received within 60 days of "pre" specimen. Mark specimens clearly as "Pre-Vaccine" or "Post-Vaccine". 
Storage/Transport Temperature
Unacceptable Conditions
Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens. 
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) 
Reference Interval
Antibody concentration of > 0.1 IU/mL is usually considered protective.
Interpretive Data
Responder status is determined according to the ratio of a one-month post-vaccination specimen to pre-vaccination concentration of tetanus IgG antibodies as follows:

1. If the post-vaccination concentration is less than 1.0 IU, the patient is considered a nonresponder.
2. If the post-vaccination concentration is greater than or equal to 1.0 IU, a patient with a ratio of less than 1.5 is a nonresponder, a ratio of 1.5 to less than 3.0, a weak responder, and a ratio of 3.0 or greater, a good responder.
3. If the pre-vaccination concentration is greater than 1.0, it may be difficult to assess the response based on a ratio alone. A post-vaccination concentration above 2.5 IU in this case is usually adequate.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Component Test Code*Component Chart NameLOINC
0050535Tetanus Antibody, IgG53935-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Anti-tetanus toxoid IgG
  • C. tetani
  • Clostridium tetani
  • Tetanus Immune Response
  • Tetanus toxoid antibodies
  • Tetanus Vaccine Response